OBJECTIVEPhysical activity (PA) can improve cardiovascular risk in the general population and in patients with type 2 diabetes. Studies also indicate an HbA 1c -lowering effect in patients with type 2 diabetes. Since reports in patients with type 1 diabetes are scarce, this analysis aimed to investigate whether there is an association between PA and glycemic control or cardiovascular risk in subjects with type 1 diabetes.
RESEARCH DESIGN AND METHODSA total of 18,028 adults ( ‡18 to <80 years of age) from Germany and Austria with type 1 diabetes from the Diabetes-Patienten-Verlaufsdokumentation (DPV) database were included. Patients were stratified according to their self-reported frequency of PA (PA0, inactive; PA1, one to two times per week; PA2, more than two times per week). Multivariable regression models were applied for glycemic control, diabetes-related comorbidities, and cardiovascular risk factors. Data were adjusted for sex, age, and diabetes duration. P values for trend were given. SAS 9.4 was used for statistical analysis.
RESULTSAn inverse association between PA and HbA 1c , diabetic ketoacidosis, BMI, dyslipidemia (all P < 0.0001), and hypertension (P = 0.0150), as well as between PA and retinopathy or microalbuminuria (both P < 0.0001), was present. Severe hypoglycemia (assistance required) did not differ in PA groups (P = 0.8989), whereas severe hypoglycemia with coma was inversely associated with PA (P < 0.0001).
CONCLUSIONSPA seemed to be beneficial with respect to glycemic control, diabetes-related comorbidities, and cardiovascular risk factors without an increase of adverse events. Hence, our data underscore the recommendation for subjects with type 1 diabetes to perform regular PA.
One third of the patients with DFS had an amputation of the lower extremity. Especially neuropathy or peripheral vascular disease was more prevalent in patients with DFS. New concepts to prevent DFS-induced amputations and to reduce cardiovascular risk factors before the occurrence of DFS are necessary.
During the COVID-19 pandemic, there were increased concerns about glycemic
control in patients with diabetes. Therefore, we aimed to assess changes in
diabetes management during the COVID-19 lockdown for patients with type 1 or
type 2 diabetes mellitus (T1DM, T2DM) in Germany. We included data from 24,623
patients (age>18 years) with T1DM (N=6,975) or T2DM
(N=17,648) with documented data in 2019 and 2020 from the multicenter
Diabetes-Prospective Follow-up registry (DPV). We conducted a groupwise
comparison of identical patients in 2019 and 2020 for different time periods of
pandemia. Pairwise differences of continuous parameters of treatment modalities
and metabolic outcome between 2019 and 2020 were adjusted for seasonality, age,
and diabetes duration. We presented these outcomes as adjusted medians with
95% confidence intervals. Rates were compared using negative-binomial
models, dichotomous outcomes were compared using logistic models. Models were
additionally adjusted for age and diabetes duration. These outcomes were
presented as least-square means with 95% confidence intervals, p-values
of<.05 were considered significant.In participants with T1DM, CGI (combined glucose indicator) increased only by
0.11–0.12% in all time periods of 2020 compared to 2019 (all
p<0.001) while BMI decreased slightly by −(0.09–0.10)
kg/m² (p<0.0001). In participants with T2DM, HbA1c
increased by 0.12%, while BMI decreased slightly by
−(0.05–0.06) kg/m² (p<0.0001).During the COVID-19 lockdown period, patients with T1DM and T2DM experienced only
clinically insignificant changes in glucose control or body weight. Despite
lockdown restrictions, patients were able to maintain metabolic control.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.